title: Long-term durability of molecular and chimerism responses in patients treated with imatinib for chronic myeloid leukemia relapse after allogeneic transplantation.
authors.forename: Vanesa
authors.initials: V
authors.lastname: Martín-Palanco
authors.forename: Francisco
authors.initials: F
authors.lastname: Martínez
authors.forename: Victor
authors.initials: V
authors.lastname: Arqueros
authors.forename: Antonio
authors.initials: A
authors.lastname: Torres
authors.forename: José
authors.initials: J
authors.lastname: Román-Gómez
mesh_terms: D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D002648:Child; D003131:Combined Modality Therapy; D005260:Female; D016313:Genes, abl; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics* / Q000628:therapy*; D017710:Lymphocyte Transfusion; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012008:Recurrence; D033581:Stem Cell Transplantation; D013997:Time Factors; D018183:Transplantation Chimera; D014184:Transplantation, Homologous; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate